The increasing rates of obesity, diabetes, and metabolic syndrome in the United States are leading to more cases of non-alcoholic fatty liver disease (NAFLD) and its most aggressive subtype, non-alcoholic steatohepatitis (NASH), which are now being encountered at a greater frequency in clinical practice. NASH can lead to significant morbidity and mortality, including liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)—in fact, HCC caused by NASH is poised to become the leading cause of liver transplants in the US.
Significant advances have been made in our understanding of NAFLD/NASH pathophysiology, risk factors, disease progression, leading to newer diagnostic approaches and therapeutic targets. However, navigating these developments is no easy feat--for example, there are now more than 150 clinical trials for NASH. Are we getting closer to a treatment for NASH? What does the future look like? What can we do now to treat NASH? Who is responsible for screening and diagnosing NASH? Participate in this interactive meeting to get feedback from experts on these important topics and much more.
About CMHC Live Online
CMHC Live Online is a series of CME/CE live and archived online learning events directly connecting attendees to the foremost experts in cardiometabolic health from the setting of their choosing. Through an interactive and easy-to-navigate online format, CMHC Live Online will provide the opportunity to join world-renowned clinical practitioners, researchers, and educators in taking a deep investigative dive into the latest knowledge in cardiometabolic health available.
Plus, CMHC Live Online will be recorded and archived for one year, providing attendees that participated in the livestream with opportunities to revisit the sessions, as well as those unable to attend the livestream with the option to watch the archived sessions and receive credit for up to one year.